Sort
172,184 grants matching “inflammation”
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
$999,799Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2023 · HL
Thyroid Cancer Aggressiveness in WTC Responders
$999,774Emanuela Taioli · Icahn School Of Medicine At Mount Sinai · U01 · FY2019 · OH
Effects of Time-restricted Eating versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers among Adults with Obesity
$999,730Lisa Tussing-Humphreys · University Of Illinois At Chicago · R01 · FY2024 · CA
Obstructive Sleep Apnea in WTC Responders: Role of Nasal Pathology
$999,725Jag Sunderram · Rbhs-Robert Wood Johnson Medical School · U01 · FY2015 · OH
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease
$999,718Edward Gomperts · Hillhurst Biopharmaceuticals, Inc. · R44 · FY2025 · HL
Humanized Antibody Therapeutic to Improve Cardiac Function Following Myocardial I
$999,700Walter Newman · Decimmune Therapeutics, Inc · R44 · FY2014 · HL
Development of TP-317 in Ulcerative Colitis
$999,696John Parkinson · Thetis Pharmaceuticals, Llc · R44 · FY2025 · DK
Obstructive Sleep Apnea in WTC Responders: Role of Nasal Pathology
$999,675Jag Sunderram · Rbhs-Robert Wood Johnson Medical School · U01 · FY2014 · OH
Clinical Utility of Endothelial Function in PAD
$999,661Boston Medical Center · R01 · FY2004 · HL
Development of TP-317 in Ulcerative Colitis
$999,624John Parkinson · Thetis Pharmaceuticals, Llc · R44 · FY2024 · DK
A Single-cell Platform for Analyzing the Peripheral Immune Response in Alzheimerâs and Alzheimerâs Related Diseases
$999,615Timothy S McConnell · Isoplexis, Inc. · R44 · FY2020 · AG
Avanzando Caminos (Leading Pathways): The Hispanic/Latino Cancer Survivorship Cohort Study.â
$999,612Frank J Penedo · University Of Miami Coral Gables · UG3 · FY2021 · CA
Bacterial-Induced Sepsis: A New Treatment Strategy
$999,605Sharon L McCoy · 13therapeutics, Inc. · R44 · FY2011 · AI
An Agnostic, Host-Direct Survival Cure MCM for Pulmonary Toxicants.
$999,601Martina Buck · Xfibra, Inc. · R44 · FY2024 · AI
Clinical Utility of Endothelial Function in PAD
$999,588Boston Medical Center · R01 · FY2005 · HL
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease
$999,578Edward Gomperts · Hillhurst Biopharmaceuticals, Inc. · R44 · FY2023 · HL
Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome
$999,491Charles Andrew Stewart · Cartesian Therapeutics, Inc. · R44 · FY2022 · HL
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
$999,425Teodora Nicola · Alveolus Bio, Inc. · R44 · FY2024 · HL
Interleukin 4
$999,413William Paul · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Bacterial-Induced Sepsis: A New Treatment Strategy
$999,411Sharon L McCoy · 13therapeutics, Inc. · R44 · FY2013 · AI
A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients
$999,362Vamsee K Pamula · Baebies, Inc. · R44 · FY2025 · HL
Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis
$999,317Ke Xu · Yale University · R01 · FY2025 · DA
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds
$999,289Gautam Sudhir Ghatnekar · Xequel Bio, Inc. · R44 · FY2014 · DK
Novel Vehicles for Targeted Cardiovascular Repair
$999,212Melina Rae Kibbe · Northwestern University At Chicago · R01 · FY2013 · HL
ENGINEERING BIOMATERIAL BASED THERAPIES FOR IMPROVED LYMPHATIC FUNCTION AND THE RESOLUTION OF CHRONIC INFLAMMATION IN POST-TRAUMATIC OSTEOARTHRITIS
$999,103Emory University · · FY2018 · Department of the Army